Safe Treatment of Pulmonary Hypertension With Bosentan in a Patient With Moyamoya Disease and Cerebral Ischemia

Abstract

A 7-year-old girl with Down syndrome and moderately severe pulmonary hypertension experienced a stroke while being treated with a calcium channel blocker. Angiography identified bilateral stenosis of the supraclinoid internal carotid arteries, stenosis or occlusion of the proximal anterior and middle cerebral arteries, and occlusion of the left posterior cerebral artery. She underwent surgery to enhance collateral blood flow to vulnerable areas of the brain. Her pulmonary hypertension therapy was changed to an oral endothelin receptor antagonist. She developed excellent collateral blood flow through external carotid arteries to each cerebral hemisphere and an improvement in blood flow through the right internal carotid artery. This case suggests that bosentan can be used safely in children with moyamoya disease. Additional studies are needed to determine whether endothelin receptor antagonists may influence the progression of moyamoya disease or the development of collateral cerebral blood flow following surgery.

Keywords

Down syndrome endothelin moyamoya disease pulmonary hypertension

Get full access to this article

View all access options for this article.

References

Humbert M. , Morrell NW , Archer SL , et al. Cellular and molecular pathobiology of pulmonary arterial hypertension . J Am Coll Cardiol. 2004;43(12supplS):13S-24S.

Suzuki J. , Takaku A. Cerebrovascular ‘‘moyamoya’’ disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288-299.

Fukui M. , Kono S. , Sueishi K. , Ikezaki K. Moyamoya disease. Neuropathology. 2000;20(suppl):S61-S64.

Masuda J. , Ogata J. , Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke. 1993;24(12): 1960-1967.

Cramer SC , Robertson RL , Dooling EC , Scott RM Moyamoya and Down syndrome. Stroke. 1996;27(11):2131-2134.

Clapp S. , Perry BL , Farooki ZQ , et al. Down’s syndrome, complete atrioventricular canal, and pulmonary vascular obstructive disease. J Thorac Cardiovasc Surg. 1990; 100(1):115-121.

Rosenzweig EB , Ivy DD , Widlitz A. , et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(4):697-704.

Fukushima Y. , Kondo Y. , Kuroki Y. , et al. Are Down syndrome patients pre-disposed to moyamoya disease? Eur J Pediatr. 1986;144(5):516-517.

Moore SW , Johnson AG Hirschsprung’s disease: genetic and functional associations of Down’s and Waardenburg syndromes. Semin Pediatr Surg. 1998;7(3):156-161.

10.

Puffenberger EG , Hosoda K. , Washington SS , et al. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung’s disease. Cell. 1994;79(7):1257-1266.

11.

Yamauchi T. , Tada M. , Houkin K. , et al. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke. 2000;31(4): 930-935.

12.

Ikeda H. , Sasaki T. , Yoshimoto T. , Fukui M. , Arinami T. Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet. 1999;64(2):533-537.

13.

Sakurai K. , Horiuchi Y. , Ikeda H. , et al. A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet. 2004;49(5):278-281.

14.

Inoue TK , Ikezaki K. , Sasazuki T. , Matsushima T. , Fukui M. Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol. 2000;15(3):179-182.

15.

Arinami T. , Ishikawa M. , Inoue A. , et al. Chromosomal assignments of the human endothelin family genes: the endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to 1p34, and the endothelin-3 gene (EDN3) to 20q13.2-q13.3. Am J Hum Genet. 1991;48(5):990-996.

16.

Houkin K. , Yoshimoto T. , Abe H. , et al. Role of basic fibroblast growth factor in the pathogenesis of moyamoya disease. Neurosurg Focus. 1998;5(5):e2.

17.

Hafizi S. , Allen SP , Goodwin AT , Chester AH , Yacoub MH Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the ET(A) receptor and is co-mitogenic with growth factors. Atherosclerosis. 1999;146(2):351-359.